Cargando…

The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme

Avermectins are macrocyclic lactones with anthelmintic activity. Recently, they were found to be effective against Mycobacterium tuberculosis, which accounts for one third of the worldwide deaths from antimicrobial resistance. However, their anti-mycobacterial mode of action remains to be elucidated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezquerra-Aznárez, José Manuel, Degiacomi, Giulia, Gašparovič, Henrich, Stelitano, Giovanni, Sammartino, Josè Camilla, Korduláková, Jana, Governa, Paolo, Manetti, Fabrizio, Pasca, Maria Rosalia, Chiarelli, Laurent Roberto, Ramón-García, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776228/ https://www.ncbi.nlm.nih.gov/pubmed/35054958 http://dx.doi.org/10.3390/ijms23020771

Ejemplares similares

Structure, Dynamics, and Interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 Examined by Molecular Modeling, Simulation, and Electrostatic Studies
por: Bhutani, Isha, et al.
Publicado: (2015)

Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro
por: Sarathy, Jickky Palmae, et al.
Publicado: (2022)

Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
por: Chikhale, Rupesh V, et al.
Publicado: (2014)

Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis
por: Batt, Sarah M., et al.
Publicado: (2023)

Virtual Screening of Small Molecular Inhibitors against DprE1
por: Zhang, Gang, et al.
Publicado: (2018)

Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1
por: Richter, Adrian, et al.
Publicado: (2018)

Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients
por: Degiacomi, Giulia, et al.
Publicado: (2019)

Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties
por: Amado, Patrícia S. M., et al.
Publicado: (2022)

Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis
por: Piton, Jérémie, et al.
Publicado: (2018)

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes
por: Liu, Renhe, et al.
Publicado: (2017)

Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence
por: Chhabra, Sonali, et al.
Publicado: (2021)

Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis
por: Xiang, Wang, et al.
Publicado: (2023)

Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities
por: Wang, Pengxu, et al.
Publicado: (2021)

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid
por: Abrahams, Katherine A., et al.
Publicado: (2023)

In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates
por: Degiacomi, Giulia, et al.
Publicado: (2020)

Synthesis and Structure–Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents
por: Yadav, Veena D., et al.
Publicado: (2023)

CanB, a Druggable Cellular Target in Mycobacterium tuberculosis
por: Degiacomi, Giulia, et al.
Publicado: (2023)

Decaprenyl-phosphoryl-ribose 2′-epimerase (DprE1): challenging target for antitubercular drug discovery
por: Gawad, Jineetkumar, et al.
Publicado: (2018)

Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options
por: Recchia, Deborah, et al.
Publicado: (2023)

OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor
por: Hariguchi, Norimitsu, et al.
Publicado: (2020)

Identification of hydantoin based Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools
por: Mali, Suraj N., et al.
Publicado: (2022)

The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism
por: Degiacomi, Giulia, et al.
Publicado: (2021)

Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model
por: Ramey, Michelle E., et al.
Publicado: (2023)

Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug
por: Mori, Giorgia, et al.
Publicado: (2020)

Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis
por: Stelitano, Giovanni, et al.
Publicado: (2020)

Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832
por: Robertson, Gregory T., et al.
Publicado: (2021)

A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis
por: Salina, Elena G., et al.
Publicado: (2022)

New Drugs and Novel Cellular Targets against Tuberculosis
por: Degiacomi, Giulia, et al.
Publicado: (2022)

Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment
por: Scherr, Nicole, et al.
Publicado: (2015)

Synthesis, biological evaluation and molecular docking studies of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives as novel antitubercular agents: future DprE1 inhibitors
por: Gawad, Jineetkumar, et al.
Publicado: (2018)

DER NEWSLETTER DES DPR
Publicado: (2022)

Treatment of rabbit cheyletiellosis with selamectin or ivermectin: a retrospective case study
por: Mellgren, Marianne, et al.
Publicado: (2008)

Unexpected effects of ivermectin and selamectin on inducible Cre(ER) activity in mice
por: Kropp, Peter A., et al.
Publicado: (2020)

A review of the off-label use of selamectin (Stronghold(®)/Revolution(®)) in dogs and cats
por: Fisher, Maggie A, et al.
Publicado: (2008)

Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired Staphylococcus aureus Infections
por: Folliero, Veronica, et al.
Publicado: (2023)

The Two-Component Locus MSMEG_0244/0246 Together With MSMEG_0243 Affects Biofilm Assembly in M. smegmatis Correlating With Changes in Phosphatidylinositol Mannosides Acylation
por: Li, Miaomaio, et al.
Publicado: (2020)

Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression
por: Degiacomi, Giulia, et al.
Publicado: (2017)

Safety and efficacy of a new spot-on formulation of selamectin plus sarolaner in the treatment and control of naturally occurring flea infestations in cats presented as veterinary patients in Australia
por: Packianathan, Raj, et al.
Publicado: (2020)

Resolution enhancement with deblurring by pixel reassignment (DPR)
por: Zhao, Bingying, et al.
Publicado: (2023)

Successful treatment of otodemodicosis due to Demodex cati with sarolaner/selamectin topical solution in a cat
por: Simpson, Andrew C
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nu3g58fs82tcge0kh1c66a69e1